HCC-2998 Xenograft Model Service for Colon Cancer

The HCC-2998 xenograft model represents a robust and clinically relevant preclinical platform for colon cancer drug development, offering researchers a highly characterized system to evaluate therapeutic efficacy and tumor biology. Alfa Cytology delivers comprehensive HCC-2998 xenograft model services tailored to your preclinical research needs, leveraging validated protocols and rigorous quality control to accelerate your oncology pipeline from candidate selection to IND-enabling studies.

Overview of HCC-2998 Xenograft Model for Colon Cancer

HCC-2998 is a human colon adenocarcinoma cell line originally established from a patient-derived tumor specimen and subsequently incorporated into the NCI-60 panel, one of the most extensively characterized collections of human cancer cell lines used for anticancer drug screening. This cell line exhibits epithelial morphology and represents a highly differentiated colon carcinoma phenotype, making it a valuable tool for preclinical investigations into colorectal cancer pathogenesis, drug resistance mechanisms, and novel therapeutic strategies. Genomic profiling reveals that HCC-2998 harbors a substantial mutation burden with approximately 5,079 genetic mutations, including variants in key signaling pathways such as PI3K/AKT, TP53, ATM, and KRAS (A146T), which contribute to its distinct drug sensitivity profile and biological behavior.

When implanted into immunodeficient murine hosts, HCC-2998 cells reliably form subcutaneous or orthotopic xenograft tumors that recapitulate essential features of human colon adenocarcinoma, including glandular architecture, moderate proliferation rates, and responsiveness to standard-of-care chemotherapeutics such as 5-fluorouracil. The model has been widely employed in NCI-sponsored drug screening programs and independent academic studies to evaluate compound efficacy, pharmacokinetic properties, and combination regimens. Its well-documented molecular characteristics and consistent tumor growth kinetics render the HCC-2998 xenograft an indispensable asset for translational oncology research aimed at bridging the gap between in vitro findings and in vivo therapeutic outcomes.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through PI3K/AKT, TP53, and KRAS A146T mutations, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for high mutation burden tumors.

Figure 1. PELP1 expression was upregulated in CRC. (Ning, Z, et al., 2014)

Cell Line Information: HCC-2998

The HCC-2998 cell line is a well-established human colon adenocarcinoma line with comprehensive molecular characterization. Its classification within the NCI-60 panel, high mutation burden, and non-canonical KRAS A146T variant make it unique among available colon cancer cell lines and essential for preclinical research targeting highly differentiated colorectal carcinoma.

Our Services

Alfa Cytology specializes in the development and execution of HCC-2998 xenograft studies for preclinical colon cancer research, offering end-to-end services that encompass cell line authentication, tumor implantation, in-life monitoring, efficacy assessment, and comprehensive histopathological and biomarker endpoint analysis. Our experienced team ensures rigorous protocol adherence and data integrity to support your drug discovery and development objectives.

Workflow of HCC-2998 Xenograft Model Construction

The construction of HCC-2998 xenograft models follows a standardized yet adaptable workflow designed to ensure reproducible tumor growth, animal welfare compliance, and high-quality preclinical data generation. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Preparation: HCC-2998 cells are recovered from cryogenic storage and expanded under standard culture conditions. Short tandem repeat (STR) profiling and mycoplasma testing are performed to confirm cell identity and sterility prior to implantation.
2. Host Selection and Acclimation: Immunodeficient mice (typically NOD-scid gamma [NSG] or athymic nude mice) are selected based on study objectives and acclimated for 5--7 days. Health status is verified by veterinary assessment before tumor cell inoculation.
3. Tumor Cell Inoculation: HCC-2998 cells are harvested at logarithmic growth phase, washed, and resuspended in serum-free medium mixed with Matrigel or PBS at an optimized concentration (typically 2--5 x 10^6 cells per injection). The cell suspension is implanted subcutaneously into the flank or orthotopically into the cecal wall, depending on the study design.
4. Tumor Monitoring and Randomization: Tumor growth is monitored by caliper measurement every 2--3 days until tumors reach a palpable volume (approximately 100--150 mm^3). Mice are then randomized into treatment and vehicle control groups to ensure balanced baseline tumor volumes.
5. Dosing and In-Life Assessments: Test compounds are administered via the designated route (oral gavage, intraperitoneal, or intravenous) according to the study protocol. Body weight, clinical signs, and tumor dimensions are recorded throughout the dosing period to evaluate tolerability and antitumor activity.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathology (H&E, IHC), biomarker analysis (Western blot, qPCR, flow cytometry), and pharmacokinetic profiling. Blood and major organs are collected for toxicity assessment.

Figure 2: Schematic workflow illustrating the derivation and construction of the HCC-2998 Xenograft Model at Alfa Cytology.

Case Study-HCC-2998 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology established HCC-2998 subcutaneous xenografts in NSG mice to evaluate the efficacy of a novel targeted therapeutic agent. Tumors were successfully engrafted with a take rate exceeding 90%, and dose-dependent tumor growth inhibition was observed across multiple treatment cohorts. Comprehensive endpoint analyses included tumor volume regression curves, body weight monitoring, histopathological evaluation of necrosis and proliferation indices, and biomarker quantification of relevant signaling pathway components. Detailed study parameters and quantitative results are available upon request under confidentiality agreement.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your HCC-2998 xenograft model studies provides access to a dedicated preclinical CRO committed to scientific excellence, operational transparency, and client-focused project management. Our integrated service model is designed to deliver actionable data within defined timelines while maintaining the highest standards of animal welfare and regulatory compliance.

• Verified Cell Line Integrity: Validated HCC-2998 cell line stocks with authenticated STR profiles and confirmed mycoplasma-negative status.
• High Take Rates and Consistency: Customizable study designs encompassing subcutaneous, orthotopic, and patient-derived xenograft (PDX) formats.
• Comprehensive Analytical Support: Experienced in vivo oncology team with proven track record in NCI-60 panel xenograft model execution.
• Tailored Study Designs: Comprehensive endpoint analysis including histopathology, immunohistochemistry, biomarker profiling, and PK/PD correlation.
• Standardized Protocols: Rigorous quality control and GLP-compliant data documentation to support IND submissions and regulatory filings.
• Dedicated Project Management: Dedicated project management ensuring transparent communication, milestone tracking, and timely delivery of study reports.

Contact Us

Ready to advance your colon cancer therapeutic pipeline with a validated HCC-2998 xenograft model? Contact us today to discuss your preclinical study requirements, receive a customized proposal, and learn how Alfa Cytology can accelerate your path from bench to bedside. Please reach out to us today via our inquiry form or email to learn more about our HCC-2998 Xenograft Model services.

For research use only. Not intended for any clinical use.